Cargando…

FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk

INTRODUCTION: The biological actions of vitamin D are mediated through vitamin D receptor (VDR). Numerous single-nucleotide polymorphisms (SNPs) in the VDR gene have been identified, and some have been associated with cardiovascular disease (CVD) risk factors. This study aims to evaluate the associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakhl, Sahar, Sleilaty, Ghassan, Chouery, Eliane, Salem, Nabiha, Chahine, Ramez, Farès, Nassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191939/
https://www.ncbi.nlm.nih.gov/pubmed/32368685
http://dx.doi.org/10.5114/amsad.2019.91437
_version_ 1783527937815871488
author Nakhl, Sahar
Sleilaty, Ghassan
Chouery, Eliane
Salem, Nabiha
Chahine, Ramez
Farès, Nassim
author_facet Nakhl, Sahar
Sleilaty, Ghassan
Chouery, Eliane
Salem, Nabiha
Chahine, Ramez
Farès, Nassim
author_sort Nakhl, Sahar
collection PubMed
description INTRODUCTION: The biological actions of vitamin D are mediated through vitamin D receptor (VDR). Numerous single-nucleotide polymorphisms (SNPs) in the VDR gene have been identified, and some have been associated with cardiovascular disease (CVD) risk factors. This study aims to evaluate the association of five SNPs in the VDR gene with 25-hydroxyvitamin D (25[OH]D) levels in patients with at least one CVD risk factor. MATERIAL AND METHODS: Genomic DNA was sequenced using standard Sanger methods for five VDR SNPs (BsmI rs1544410; ApaI rs7975232; Cdx2 rs11568820; TaqI rs731236; FokI rs2228570) in 50 Mediterranean subjects having hypovitaminosis D with at least one documented CVD risk factor, aged 18 years or more. The collected variables were serum levels of (25[OH]D), HbA(1c), fasting plasma glucose, triglycerides, LDL cholesterol, and total cholesterol. RESULTS: BsmI, ApaI, and TaqI were moderately to highly intercorrelated. Cdx2 was less frequent than expected. With respect to the number of mutations in FokI, levels of (25 [OH]D) were 11.2 ±5.5 ng/ml in the absence of mutations, 12.6 ±4.7 ng/ml in the presence of one mutation, and 16.5 ± 5.5 ng/ml in the presence of two mutations. CONCLUSIONS: FokI polymorphism is more frequent in subjects with cardiovascular risk factors than in the general Caucasian population.
format Online
Article
Text
id pubmed-7191939
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-71919392020-05-04 FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk Nakhl, Sahar Sleilaty, Ghassan Chouery, Eliane Salem, Nabiha Chahine, Ramez Farès, Nassim Arch Med Sci Atheroscler Dis Clinical Research INTRODUCTION: The biological actions of vitamin D are mediated through vitamin D receptor (VDR). Numerous single-nucleotide polymorphisms (SNPs) in the VDR gene have been identified, and some have been associated with cardiovascular disease (CVD) risk factors. This study aims to evaluate the association of five SNPs in the VDR gene with 25-hydroxyvitamin D (25[OH]D) levels in patients with at least one CVD risk factor. MATERIAL AND METHODS: Genomic DNA was sequenced using standard Sanger methods for five VDR SNPs (BsmI rs1544410; ApaI rs7975232; Cdx2 rs11568820; TaqI rs731236; FokI rs2228570) in 50 Mediterranean subjects having hypovitaminosis D with at least one documented CVD risk factor, aged 18 years or more. The collected variables were serum levels of (25[OH]D), HbA(1c), fasting plasma glucose, triglycerides, LDL cholesterol, and total cholesterol. RESULTS: BsmI, ApaI, and TaqI were moderately to highly intercorrelated. Cdx2 was less frequent than expected. With respect to the number of mutations in FokI, levels of (25 [OH]D) were 11.2 ±5.5 ng/ml in the absence of mutations, 12.6 ±4.7 ng/ml in the presence of one mutation, and 16.5 ± 5.5 ng/ml in the presence of two mutations. CONCLUSIONS: FokI polymorphism is more frequent in subjects with cardiovascular risk factors than in the general Caucasian population. Termedia Publishing House 2019-12-31 /pmc/articles/PMC7191939/ /pubmed/32368685 http://dx.doi.org/10.5114/amsad.2019.91437 Text en Copyright © 2019 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Clinical Research
Nakhl, Sahar
Sleilaty, Ghassan
Chouery, Eliane
Salem, Nabiha
Chahine, Ramez
Farès, Nassim
FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk
title FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk
title_full FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk
title_fullStr FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk
title_full_unstemmed FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk
title_short FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk
title_sort foki vitamin d receptor gene polymorphism and serum 25-hydroxyvitamin d in patients with cardiovascular risk
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191939/
https://www.ncbi.nlm.nih.gov/pubmed/32368685
http://dx.doi.org/10.5114/amsad.2019.91437
work_keys_str_mv AT nakhlsahar fokivitamindreceptorgenepolymorphismandserum25hydroxyvitamindinpatientswithcardiovascularrisk
AT sleilatyghassan fokivitamindreceptorgenepolymorphismandserum25hydroxyvitamindinpatientswithcardiovascularrisk
AT choueryeliane fokivitamindreceptorgenepolymorphismandserum25hydroxyvitamindinpatientswithcardiovascularrisk
AT salemnabiha fokivitamindreceptorgenepolymorphismandserum25hydroxyvitamindinpatientswithcardiovascularrisk
AT chahineramez fokivitamindreceptorgenepolymorphismandserum25hydroxyvitamindinpatientswithcardiovascularrisk
AT faresnassim fokivitamindreceptorgenepolymorphismandserum25hydroxyvitamindinpatientswithcardiovascularrisk